Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
|Podcasts|September 14, 2012
Playing God in the Hospital (Podcast)
Author(s)Richard M. Berlin, MD
His pager calls. Code Blue. And for no reason at all, he lifts the window and blows a little life back into the world.
Advertisement
Playing God in the Hospital
A fly buzzes
black complaints
at the glass.
Drawn by sunlight
reflected off snow,
it's trapped
without design
to know another way.
My pager calls
Code Blue.
And for no reason
at all
I lift the window
and blow a little life
back into the world.
For more on this poem, click
Advertisement
Related to this article
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
3
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
4
The New, Impending Adult ADHD Guidelines
5